Clinical Trial Update: A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for Paclitaxel (Albumin-binding) in castration-resistant prostate cancer spanning Phase 1/2, with limited status information available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Paclitaxel (Albumin-binding) (paclitaxel albumin-bound)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: UNKNOWN